Sign In
Buy RXRX
$3.52
+0.180 (+5.39%)
At Close: Jun 26, 2026
What's in Store for These 5 Medical Companies This Earnings Season?
10:11am, Monday, 23'rd Feb 2026
IRWD, RXRX, NVAX, VTRS and NTLA gear up for earnings as the Medical sector posts solid sales growth despite a slight profit dip so far.
Recursion To Be Featured in HighRes' Lightning Talk at NVIDIA GTC
08:00am, Monday, 23'rd Feb 2026
Salt Lake City, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will be featured in
Recursion to Participate in Upcoming Investor Conferences
07:55am, Monday, 23'rd Feb 2026
Salt Lake City, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its participation in t
Cathie Wood Goes Bargain Hunting: 3 Stocks She Just Bought
10:02am, Sunday, 22'nd Feb 2026
Cathie Wood's Ark Invest bought shares in Figma, CoreWeave, and Recursion Pharmaceuticals on Friday. Figma stock has fallen 30% this year, but it's been rising in recent days with a strong quarterly r
Cathie Wood Pours $24 Million to This AI Software Stock
10:01am, Friday, 20'th Feb 2026
Cathie Wood's ARK Invest added to Figma (FIG) and trimmed DraftKings (DKNG) on Feb. 19, as part of a broader portfolio reshuffle.ARK funds bought about $24 mill
Recursion Pharmaceuticals (RXRX) Expected to Announce Quarterly Earnings on Friday
01:49am, Friday, 20'th Feb 2026
Recursion Pharmaceuticals (NASDAQ: RXRX - Get Free Report) is projected to issue its Q4 2025 results before the market opens on Friday, February 27th. Analysts expect the company to announce earnings
Recursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to Consider
06:50pm, Wednesday, 18'th Feb 2026
In the most recent trading session, Recursion Pharmaceuticals (RXRX) closed at $3.53, indicating a +2.02% shift from the previous trading day.
Recursion Pharmaceuticals Stock Drops: What's Behind It?
02:07pm, Wednesday, 18'th Feb 2026
Recursion Pharmaceuticals Inc (NASDAQ: RXRX) shares are under pressure Wednesday after new regulatory filings showed that Nvidia Corp (NASDAQ: NVDA) has fully exited its investment in the AI‑focused
Recursion to Report Fourth Quarter and Full Year 2025 Business Updates and Financial Results on February 25
08:30am, Wednesday, 18'th Feb 2026
Company to host public (L)earnings call on February 25 at 8:00 am ET / 6:00 am MT / 1:00 pm GMT Company to host public (L)earnings call on February 25 at 8:00 am ET / 6:00 am MT / 1:00 pm GMT
Applied Digital, Recursion Pharmaceuticals Stocks Drop. Blame Nvidia.
05:43am, Wednesday, 18'th Feb 2026
Nvidia disclosed in a filing on Tuesday that it no longer held shares in Applied Digital, drug-discovery company Recursion Pharmaceuticals and autonomous-driving company WeRide.
2 Biotech Stocks to Buy as AI Drug Discovery Lifts Off
10:00am, Thursday, 12'th Feb 2026
AI-assisted drug discovery isn't just science fiction anymore, especially as biotechnology and biopharma firms embrace the AI age.
Baillie Gifford's Strategic Adjustment in Recursion Pharmaceuticals Inc
07:37pm, Wednesday, 11'th Feb 2026
Transaction Overview On December 31, 2025, Baillie Gifford (Trades, Portfolio) executed a strategic transaction involving Recursion Pharmaceuticals Inc (RXRX).
Recursion Pharmaceuticals (RXRX) Falls More Steeply Than Broader Market: What Investors Need to Know
06:45pm, Tuesday, 10'th Feb 2026
Recursion Pharmaceuticals (RXRX) closed the most recent trading day at $3.85, moving 3.27% from the previous trading session.
Brokerages Set Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Price Target at $9.40
01:32am, Sunday, 08'th Feb 2026
Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX - Get Free Report) have earned a consensus rating of "Hold" from the six research firms that are presently covering the company, Marketbeat.com
This $4 Stock Could Be Your Ticket to Millionaire Status
03:35pm, Saturday, 07'th Feb 2026
It comes as no surprise that artificial intelligence is at the heart of the opportunity. This application of AI, in fact, is arguably one of the best uses of this young technology.
